Lilly and Boehringer roll toward EU approval with diabetes combo

Eli Lilly ($LLY) and Boehringer Ingelheim secured a recommendation from European regulators for their combination diabetes treatment, making for a likely continental approval in the coming months. The drug is a fixed-dose combination of empagliflozin, an SGLT-2 inhibitor that forces excess blood sugars out through the urine, and metformin, a long-generic treatment designed to block glucose production in the liver. The pair plans to market the combination as Synjardy, expecting to pick up FDA approval later this year. Empagliflozin won approval last year and is marketed as Jardiance. More

Suggested Articles

A new clinical hold is the latest setback for Solid Biosciences and the development of its gene therapy for Duchenne muscular dystrophy.

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.